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Abstract
Background: Selective outcome reporting and publication bias threaten the validity of systematic reviews and
meta-analyses and can affect clinical decision-making. A rigorous method to evaluate the impact of this bias on the
results of network meta-analyses of interventions is lacking. We present a tool to assess the Risk Of Bias due to
Missing Evidence in Network meta-analysis (ROB-MEN).
Methods: ROB-MEN first evaluates the risk of bias due to missing evidence for each of the possible pairwise
comparison that can be made between the interventions in the network. This step considers possible bias due to
the presence of studies with unavailable results (within-study assessment of bias) and the potential for unpublished
studies (across-study assessment of bias). The second step combines the judgements about the risk of bias due to
missing evidence in pairwise comparisons with (i) the contribution of direct comparisons to the network meta-
analysis estimates, (ii) possible small-study effects evaluated by network meta-regression, and (iii) any bias from
unobserved comparisons. Then, a level of “low risk”, “some concerns”, or “high risk” for the bias due to missing
evidence is assigned to each estimate, which is our tool’s final output.
Results: We describe the methodology of ROB-MEN step-by-step using an illustrative example from a published
NMA of non-diagnostic modalities for the detection of coronary artery disease in patients with low risk acute
coronary syndrome. We also report a full application of the tool on a larger and more complex published network
of 18 drugs from head-to-head studies for the acute treatment of adults with major depressive disorder.
Conclusions: ROB-MEN is the first tool for evaluating the risk of bias due to missing evidence in network meta-
analysis and applies to networks of all sizes and geometry. The use of ROB-MEN is facilitated by an R Shiny web
application that produces the Pairwise Comparisons and ROB-MEN Table and is incorporated in the reporting bias
domain of the CINeMA framework and software.
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Background
A challenging issue in evidence-based medicine is the
bias introduced by the selective non-reporting of pri-
mary studies or results. Failure to report all findings can
lead to results being missing from a meta-analysis. Either
a whole study may remain unpublished, commonly re-
ferred to as ‘publication bias’, or specific results may not
be reported in a publication, usually referred to as ‘se-
lective outcome reporting bias’ or ‘selective non-
reporting of results’.
Several methods are available to investigate such bias
in pairwise meta-analysis [1]. These include generic ap-
proaches, for example, comparisons of study protocols
with published reports and comparison of results ob-
tained from published versus unpublished sources, as
well as statistical methods (e.g. funnel plots [2–4], tests
for small-study effects [2, 5–7] and selection models [8,
9]). Recently, a tool to evaluate Risk Of Bias due to Miss-
ing Evidence (ROB-ME) integrated these approaches
into an overall assessment of the risk of bias due to
missing evidence in pairwise meta-analysis [10].
Network meta-analysis extends pairwise meta-analysis
to enable multiple treatments comparison by combining
direct and indirect evidence within a network of rando-
mised trials or other comparative studies. Several of the
numerical approaches to evaluate bias developed for
pairwise meta-analysis have been adapted to the network
meta-analysis setting [11–15]. Still, a rigorous method-
ology for assessing the risk of bias due to missing results
in network meta-analysis estimates is currently lacking.
To address this gap, we developed the Risk Of Bias
due to Missing Evidence in Network meta-analysis
(ROB-MEN) tool, which incorporates qualitative and
quantitative methods. We assume that investigators as-
sembled studies into a coherent network according to a
pre-specified protocol, checked the assumptions and
deemed them plausible and used appropriate statistical
methods to obtain relative treatment effects for pairs of
interventions. Then, ROB-MEN can be used to assess
the risk of bias due to missing evidence in each of the
relative treatment effects estimated in network meta-
analysis. We illustrate the ROB-MEN approach step by
step using a network meta-analysis of non-invasive diag-
nostic tests for coronary artery disease [16]. We also re-
port an application of the tool to a network of 18
antidepressants from head-to-head studies [17].
Methods
The ROB-MEN tool was developed between April and
November 2020 within the CINeMA framework to
evaluate confidence in results from network meta-
analysis [18, 19]. The authors are epidemiologists, statis-
ticians, systematic reviewers, trialists, and health services
researchers, many of whom are involved with Cochrane
systematic reviews, methods groups, and training events.
The initial proposal drew on existing methods for asses-
sing selective outcome reporting bias [20] and publica-
tion bias [2, 5, 8] in pairwise meta-analysis, as
summarised in the Cochrane Handbook for Systematic
Reviews of Interventions [1]. A draft tool was developed
in line with the preliminary version of the ROB-ME tool
[10] and presented to all co-authors. Improvements and
modifications were informed by relevant methodological
literature, previously published tools for assessing meth-
odological quality of meta-analyses and by the authors’
experience of developing tools to assess the risk of bias
in randomised and non-randomised studies, and system-
atic reviews [21, 22]. The group met several times to dis-
cuss the approach and agreed on the tool’s structure,
content, and step-wise application. An R Shiny web ap-
plication to facilitate the implementation of ROB-MEN
for the users was developed alongside the tool’s concep-
tual framework by two of the co-authors and checked by
the whole group. Refinements were made following feed-
back received also from training and research events.
We outline the methodology using the example of a net-
work of randomised controlled trials comparing non-
invasive diagnostic strategies for the detection of coronary
artery disease in patients presenting with symptoms sug-
gestive of an acute coronary syndrome [16]. The outcome
of interest is referral to coronary angiography, for which
the network included 18 trials comparing exercise electro-
cardiogram (ECG), single-photon emission computed
tomography-myocardial perfusion imaging (SPECT-MPI),
coronary computed tomographic angiography (CCTA),
cardiovascular magnetic resonance (CMR), stress echocar-
diography (Stress echo), and standard care. Standard care
was based on the discretion of the clinicians or local diag-
nostic strategies. The network graph is shown in Fig. 1a,
and a summary of the network meta-analysis methods
and results is available in Additional file 1.
Overview of ROB-MEN
In ROB-MEN, ‘bias due to missing evidence’ refers to
bias arising when some study results are unavailable be-
cause of their results. This situation may, for example,
arise because of non-significant p-values, small magni-
tudes of effect, or harmful effects. It can be due to two
types of missing evidence, as described in the recently
developed ROB-ME tool [10]: (i) the selective reporting
of results within studies that are published or otherwise
known to exist, called “within-study assessment of bias”
in the tool; (ii) studies that remain entirely unpublished
and are not known to exist, referred to as “across-study
assessment of bias” (see also the glossary in Table 1).
In network meta-analysis, estimates of treatment ef-
fects are derived by combining direct and indirect evi-
dence. Direct evidence refers to evidence about pairs of
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treatments that have been directly compared within
studies (e.g. the 8 pairwise comparisons with data shown
in Fig. 1a). Indirect evidence refers to evidence on pairs
of treatments that is “indirectly” derived from the
sources of direct evidence via a common comparator or
chain of comparisons (Table 1). In ROB-MEN, we first
evaluate the likely risk of bias due to missing evidence
for each pairwise comparison between the interventions
of interest, irrespective of the availability of direct evi-
dence (Fig. 1b). We then consider the risk of bias from
pairwise comparisons and their contribution to each es-
timate [23] with the additional risk of bias from indirect
comparisons and any evidence of small-study effects to
evaluate the overall risk of bias due to missing evidence
in each network meta-analysis estimate.
Two tables that record the assessments for each pair-
wise comparison and each estimate are at the tool’s core:
the Pairwise Comparisons Table and the ROB-MEN
Table (see Tables 2 and 3 for examples). Both tables are
completed separately for each outcome in the review.
The Pairwise Comparisons Table facilitates the assess-
ments in the ROB-MEN Table. The output of the Pair-
wise Comparisons Table provides judgement on possible
bias due to missing evidence for each of the possible
comparisons made from the interventions in the net-
work. The ROB-MEN Table is the main output of the
tool. It combines the information from the Pairwise
Comparisons Table with (i) information about the struc-
ture and the amount of data in the network and (ii) the
potential impact of missing evidence on the network
meta-analysis results to reach an overall judgement
about the risk of bias for each estimate. Figure 2 summa-
rises the process. An R Shiny web application (https://
cinema.ispm.unibe.ch/rob-men/) facilitates the ROB-
MEN process, including creating the two core tables, as
described in Additional file 2 and Additional file 3 [24].
Fig. 1 Network plots of network meta-analysis of non-invasive diagnostic modalities for detecting coronary artery disease. a Standard network
plot. b Network graph showing risk of bias assessment for pairwise comparisons. Sizes of solid lines and nodes are proportional to number of
studies in each comparison and total sample size for each treatment, respectively. Solid lines represent the observed direct comparisons, dotted
lines represent unobserved comparisons between interventions. Green indicates no bias detected, orange indicates suspected bias favouring the
treatment indicated by the arrow. ECG: electrocardiogram; CCTA: coronary computed tomographic angiography; CMR: cardiovascular magnetic
resonance; SPECT-MPI: single-photon emission computed tomography-myocardial perfusion imaging; Stress Echo: stress echocardiography
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Risk of bias due to missing evidence in pairwise
comparisons
The assessment of bias due to missing evidence in all
possible pairwise comparisons follows the ROB-ME tool
for pairwise meta-analysis [10]. Like ROB-ME, we con-
sider the studies contributing to the network meta-
analysis of the outcome of interest and the studies con-
tributing to networks of other outcomes in a systematic
review. Such studies are informative about possible se-
lective non-reporting of the outcome being addressed in
the current network meta-analysis. ROB-MEN differs
from ROB-ME by considering all possible pairwise com-
parisons between the interventions in the network.
There may be missing evidence for any directly observed
comparisons and missing evidence for the indirect com-
parisons that were not observed among the included
studies. The possible pairwise comparisons between the
interventions involved in the network, that is, all combi-
nations of two treatments, are organised into three
groups:
A. “Observed for this outcome”: the comparisons for
which there is direct evidence contributing to the
network meta-analysis for the current outcome
B. “Observed for other outcomes”: the pairwise
comparisons for which there is direct evidence only
for other outcomes in the systematic review
C. “Unobserved”: the pairwise comparisons that have
not been investigated in any of the identified studies
in the systematic review.
These groups constitute the rows of the Pairwise
Comparisons Table for a specific outcome. Instructions
for filling in the table are summarised in
Additional file 2.
For each comparison, the first two columns report the
total number of studies with results for the current out-
come or any outcome, respectively. In brackets, we enter
the total sample size by adding up all participants rando-
mised in the studies investigating the specific compari-
son for that outcome. By definition, the unobserved
comparisons will have zero in both columns. In contrast,
those observed for other outcomes will have zero in the
first column.
The groups of comparisons are presented in Table 2
for the example of non-invasive diagnostic modalities for
the detection of coronary artery disease. Of the possible
15 comparisons, 8 were observed for the outcome of
interest. The remaining 7 were unobserved, i.e. not ob-
served for the outcome of interest or any other
outcomes.
Within-study assessment of bias due to missing evidence
The evaluation of bias due to selective non-reporting of
results within studies concerns studies identified for the
review but missing from the synthesis. They are known
to exist, but the results are unavailable: the studies re-
port on other outcomes than the outcome of interest.
The presence of selective non-reporting of results in
each study is assessed using study-specific tools such as
Step 2 of the ROB-ME tool [10, 20]. Then, the likely im-
pact of the missing results across all studies may be
assessed using two signalling questions to reach an over-
all judgement of no bias detected or suspected bias
favouring X for each comparison (Table 4). The prelim-
inary version of the ROB-ME tool describes various ap-
proaches to evaluate the within-study assessment of bias
by considering the plausibility of scenarios where study
results are or are not unavailable because of the p-value,
magnitude, or direction of the treatment effects [1, 10].
A thorough within-study assessment of bias due to
missing evidence is labour intensive but particularly
valuable as the impact of selective non-reporting or
under-reporting of results can be quantified more easily
than the impact of selective non-publication of an un-
known number of studies [1]. However, suppose the
number of studies (or the sample size) not reporting the
outcome of interest (i.e. the difference between the first
two columns in Table 2) is small compared to the num-
ber of studies (or the total sample size) reporting the
outcome (the first column in Table 2). In that case, the
Table 1 Glossary of terms
Pairwise comparisons: All treatment comparisons in the network
irrespective of the availability of data. A network with T treatments has
T(T-1)/2 pairwise comparisons. Depending on whether there are studies
reporting the studied outcome, the pairwise comparisons can be
distinguished into observed for this outcome, observed for other outcomes,
and unobserved.
Direct evidence: The evidence available (statistical information derived
from data) about a pairwise comparison that is available from direct,
within study information about that comparison.
Indirect evidence: The evidence available (statistical information
derived from data) about a pairwise comparison that is not available
from within study information, i.e. is obtained indirectly via a common
comparator or chain of comparisons.
‘Only direct’ estimate: Relative treatment effect estimated in an
network meta analysis that is derived only from direct evidence.
‘Only indirect’ estimate: Relative treatment effect estimated in an
network meta analysis that is derived only from indirect evidence.
Mixed estimate: Relative treatment effect estimated in an network
meta analysis that is derived from both direct and indirect evidence.
Network meta-analysis estimates: Estimates of relative treatment
effects derived from network meta analysis; these can be distinguished
into ‘Only direct’, ‘Only indirect’ and Mixed estimates.
Within-study assessment of bias due to missing evidence: Bias
arising from missing results due to selective outcome reporting i.e.
results being reported, but not others, within studies published or
otherwise known to exist.
Across-study assessment of bias due to missing evidence: Bias
introduced from missing studies because they are entirely unpublished
i.e. not known to exist.
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assessment of these few studies is unlikely to affect the
judgement from the within-study assessment signifi-
cantly. Reviewers may then decide to assign no bias de-
tected to the relevant comparison without carrying out
the assessment. No bias detected is also assigned when
no study is suspected of selective non-reporting or
under-reporting of results for a specific comparison (i.e.
the numbers in the first two columns are equal). For the
unobserved comparisons, the assessment is not applic-
able (“NA”, Table 2).
In the example of the non-invasive diagnosis of cor-
onary artery disease, there were no additional studies
that did not report results for the outcome of inter-
est. Therefore, we assume that there is no selective
outcome reporting bias, and we assign no bias de-
tected for the within-study assessment of bias to all
observed comparisons. In the ‘14’ section, the within-
study assessment of bias is completed using the sig-
nalling questions for additional studies not reporting
the outcome of interest.
Table 2 Pairwise Comparisons Table for the network of non-invasive diagnostic modalities for detecting coronary artery disease
Column no. 1 2 3 4 5
Pairwise
comparisons







the SR (total sample
size)
Evaluation of selective reporting







Group A: observed for this outcome
CCTA vs
exercise ECG
1 (562) 1 (562) No bias detected No bias detected No bias detected
CCTA vs
SPECT-MPI



















1 (130) 1 (130) No bias detected No bias detected No bias detected
Exercise ECG
vs stress echo
4 (1086) 4 (1086) No bias detected No bias detected No bias detected
SPECT-MPI vs
standard care
2 (4165) 2 (4165) No bias detected No bias detected No bias detected
Standard care
vs stress echo





Group B: observed for other outcomes (no studies)
Group C: Unobserved
CCTA vs CMR 0 0 NA No bias detected No bias detected
CCTA vs
stress echo






0 0 NA No bias detected No bias detected
CMR vs
SPECT-MPI
0 0 NA No bias detected No bias detected
CMR vs stress
echo













0 0 NA No bias detected No bias detected
CCTA, coronary computed tomographic angiography; CMR, cardiovascular magnetic resonance; ECG, electrocardiogram; Echo, echocardiography; SPECT-MPI,
single-photon emission computed tomography-myocardial perfusion imaging; SR, systematic review
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Across-study assessment of bias due to missing evidence
This situation refers to studies undertaken but not pub-
lished, so reviewers are unaware of them. Each compari-
son is assessed for risk of publication bias using
qualitative and quantitative considerations. First, a quali-
tative judgement is made to assign a level of no bias de-
tected or suspected bias. Conditions that may indicate
bias include:
 Failure to search for unpublished studies and grey
literature
 The meta-analysis may be based on a few positive
findings on a newly introduced drug as the early evi-
dence likely overestimates efficacy [25]
 Previous evidence may have shown the presence of
publication bias for that comparison [26]
Conditions suggesting no bias include data from un-
published studies and agreement of their findings with
those of published studies or a tradition of prospective
trial registration in the field.
For comparisons with at least 10 studies (in the first
column in Table 2), judgements can additionally
consider statistical techniques such as contour-enhanced
funnel plots [4], meta-regression models and statistical
tests for small-study effects [2, 6, 7, 27–29], or selection
models for pairwise meta-analysis (e.g. Copas [8]). These
can be useful when it is difficult to assess publication
bias reliably, e.g. when protocols and records from trial
registries were unavailable. The direction of any bias
should be noted: it will generally reflect the larger bene-
fits observed in smaller studies.
We implemented the across-study assessment of
bias in the network meta-analysis of non-invasive
diagnostic tests of coronary artery disease using quali-
tative considerations (see Additional file 4). None of
the comparisons included 10 or more studies and no
assessment using graphical or statistical methods was
therefore performed. The judgements for all compari-
sons are reported in Table 2.
Overall risk of bias for pairwise comparisons
The last step in the Pairwise Comparisons Table is to
combine the levels of risk assigned in the previous steps
into a final judgement of no bias detected or suspected
bias. In case of suspected bias, the predicted direction of
Table 3 ROB-MEN Table for the network of non-invasive diagnostic modalities for detection of coronary artery disease in patients
with low risk acute coronary syndrome
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the bias, i.e. which treatment the bias is likely to favour,
should also be specified (see Fig. 1). For the unobserved
comparisons (group C), the overall risk of bias will be
the same as the judgement made for the across-study as-
sessment of bias, as this is the only assessment applic-
able to these comparisons.
For the comparisons observed for the outcome of
interest or other outcomes (group A and B), the
overall judgement will consider qualitative assess-
ments for both the within-study and the across-
study assessment of bias. The assessment of selective
outcome reporting bias (“within-study assessment of
bias”) is likely to be the most valuable because its
impact can be quantified more easily than that of
publication bias (“across-study assessment of bias”).
The process of forming a final judgement for each
pairwise comparison is illustrated in the flowchart in
Additional file 5.
Since there was no within-study assessment of bias for
the example of non-invasive diagnosis of coronary artery
disease, the overall bias judgement will only consider the
across-study assessment of bias. The final overall risk of
bias judgements is reported in the Pairwise Comparison
Table (Table 2).
Risk of bias due to missing evidence in network meta-
analysis estimates
Once the assessments of overall bias for each pairwise
comparison are complete, we integrate them in the
assessment of risk of bias for each network estimate in
the ROB-MEN Table. We organise the estimates into
two groups, “mixed/only direct” and “only indirect”, de-
pending on the type of evidence contributing to each es-
timate (see Table 1). Here, we describe the detailed steps
for filling in the relevant column in the ROB-MEN
Table and illustrate them using the network of trials of
non-invasive coronary artery disease diagnosis. Instruc-
tions are summarised in Additional file 3.
Contribution of comparisons with suspected bias to
network meta-analysis estimates
The first step is to consider the contribution matrix of
the network. The cells of this matrix provide the per-
centage contribution that each comparison with direct
evidence (columns of the matrix) makes to the calcula-
tion of the corresponding network meta-analysis relative
treatment effect (rows of the matrix) [23]. Add-
itional file 6 shows the contribution matrix for the net-
work of non-invasive diagnosis of coronary artery
disease. Each comparison with direct evidence is com-
bined with the risk of bias as judged in the Pairwise
Comparisons Table (Table 2). This way, the percentage
contribution from direct evidence with suspected bias
(reported in the first and second column of the ROB-
MEN Table, see Table 3 for example) can be estimated.
The evaluation of the contribution from comparisons
with suspected bias is reported in the third column. Spe-
cifically, the possible levels are:
Fig. 2 Overview of the ROB-MEN process
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 No substantial contribution from bias: there is no
substantial contribution from evidence with bias
favouring one of the two treatments;
 Substantial contribution from bias balanced: there is
a substantial contribution from evidence with
suspected bias, but the biases favouring one or
the other treatment are balanced and cancel each
other out;
 Substantial contribution from bias favouring X: there
is a substantial contribution from evidence with bias
favouring one of the two treatments (say X).
In the non-invasive diagnosis of coronary artery dis-
ease network meta-analysis, we considered the contribu-
tion from biased evidence as substantially in favour of
one treatment if the relative difference between treat-
ments was at least 15%. Among the mixed estimates, five
of them have a clear separation of high contribution
coming from biased evidence between the two treat-
ments (e.g. CCTA vs SPECT-MPI). Among the indirect
estimates, only three estimates showed such clear separ-
ation (e.g. CMR vs SPECT-MPI). The relevant bias
judgements for this step are in column 3 of the ROB-
MEN Table (Table 3).
Additional risk of bias for indirect estimates
Indirect relative effects are calculated from sources of
direct evidence in the Pairwise Comparisons Table with
contributions as shown in the contribution matrix. The
absence of direct evidence for these indirect compari-
sons may lead to bias if any studies are missing for rea-
sons associated with their results. Therefore, for the
indirect estimates, we need to account for this potential
source of bias, which is represented by the final judge-
ment of the overall bias for pairwise comparisons ob-
served for other outcomes or completely unobserved in
the Pairwise Comparisons Table. We copy the final
judgements from column 5 of the Pairwise Comparisons
Table (see Table 2 for example) into column 4 of the
ROB-MEN Table (see Table 3) of our illustrative ex-
ample, and we consider only those of the indirect esti-
mates. Three estimates were at suspected bias favouring
CCTA, CMR and SPECT-MPI.
Small-study effects in network meta-analysis
To evaluate small-study effects, we run a network meta-
regression model with a measure of precision (e.g. vari-
ance or standard error) as the covariate. This model gen-
erates an adjusted relative effect by extrapolating the
regression line to the smallest observed variance (the
‘largest’ study) independently for each comparison. To
assess the presence of small-study effects, we compare
the obtained adjusted estimates with the original (un-
adjusted) estimates by looking at the overlap of their
corresponding confidence (or credible) intervals. A lack
of overlap between the two intervals (or between one es-
timate and the interval for the other estimate) is an indi-
cation that effect estimates differ between smaller and
larger studies. Note that this approach assumes there is
no other explanation for the difference between the ori-
ginal, and the adjusted estimates, i.e. other covariates do
not explain it. The evaluation of small-study effects is re-
ported in the penultimate column of the ROB-MEN
Table (Table 3), with levels indicating whether there is
evidence of small-study effects and, if so, which treat-
ment is favoured by the small studies.
For the example of non-invasive diagnostic modalities,
we ran a network meta-regression model using the vari-
ance of the estimate (pooled variance for multi-arm
studies) as a covariate to investigate small-study effects
in the whole network. The adjusted estimates via ex-
trapolation to the smallest observed variance are re-
ported in column 6 of the ROB-MEN Table next to the
original network meta-analysis summary effect (column
5 in Table 3). None of the network meta-regression esti-
mates are markedly different from their unadjusted
counterparts, and the credible intervals for estimates
overlap. Therefore, “No evidence of small-study effects”
is reported in column 7 for all the estimates.
Overall risk of bias for network meta-analysis estimates
We propose rules for assigning a final judgement on the
overall risk of bias due to missing evidence for estimates
which are described in Table 5. If there is a substantial
contribution from evidence with suspected bias (column
3), we have concerns regarding the risk of bias for that
estimate. Suppose this contribution is split between
Table 4 Signalling questions for the within-study bias assessment of comparisons observed for the outcome of interest or other
outcomes
Signalling question Responses for each comparison (groups
A and B only)
1. Was there any eligible study for which results for the outcome of interest were unavailable, likely
because of the p-value, magnitude or direction of the result generated?
Yes Yes No
2. (If Yes to the previous question) Was the amount of information omitted from the synthesis
sufficient to have a notable effect on the magnitude of the synthesised result?
Yes No -
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evidence with bias favouring one of the treatments
and evidence with bias favouring the other treatment.
In that case, the biases may cancel out, assuming the
bias is about the same in the two directions. Con-
cerns about the risk of bias are then defined by the
overall bias of unobserved comparisons in column 4
(for indirect estimates) and the evidence about small-
study effects (column 7). The final judgements for the
overall risk of bias are reported in column 8 (see
Table 3). The reviewer can decide to follow our pro-
posed rules to assign the overall risk of bias level but,
if “stricter” or “more relaxed” approaches are pre-
ferred, they can also reach their final judgement based
on their own reasoning. Whatever their reasoning,
every choice and assessment should be justified and
clearly described.
In the example of non-invasive diagnostic modalities
most of the mixed estimates have substantial contri-
butions from biased evidence favouring one of the
two treatments. Still, there was no evidence of small-
study effects for any of the estimates, so we have
some concerns about the risk of bias due to missing
evidence. The exceptions are exercise ECG vs stand-
ard care, Exercise ECG vs stress echo and SPECT-
MPI vs standard care. There, the level was decreased
to “Low risk” due to lack of substantial contribution
from biased evidence favouring either one of the two
treatments. Similarly, we assign “Some concerns” to
indirect estimates, where a substantial contribution
from biased evidence was favouring one of the two
treatments. For CMR vs stress echo, the level was in-
creased to “High risk” because of the additional bias
from the corresponding indirect comparison assessed
in the Pairwise Comparisons Table (Table 2), despite
the fact that there is no evidence of small-study ef-
fects. The other indirect estimates were assigned a
level of “Low risk” of bias because (i) there was no
substantial contribution from biased evidence or it
cancelled each other out, (ii) there was no additional
bias from the indirect comparison assessed in the
Pairwise Comparisons Table (Table 2), and (iii) there
was no evidence of small-study effects. The final
judgements on the overall risk of bias due to missing
evidence are reported in column 8 of Table 3.
Results
Application of ROB-MEN to a network of antidepressants
We applied the ROB-MEN tool to a network of head-to-
head studies (i.e. trials of active interventions) of 18 anti-
depressants [17]. The outcome of interest is the response
to treatment defined as a reduction of at least 50% in
the score between baseline and week 8 on a standardised
rating scale for depression [30].
Pairwise comparisons table
There are 153 possible comparisons between the 18
drugs. Seventy compared the response to the antidepres-
sant (group A) and 2 (amitriptyline vs bupropion and
amitriptyline vs nefazodone, group B) compared other
outcomes (dropouts and remission). The remaining 82
possible comparisons were not covered in any of the
studies (“unobserved”, group C) (see Additional file 7).
We carried out the within-study assessment of bias
due to missing evidence for the two comparisons in the
“observed for other outcomes” group (no bias detected)
and for the comparisons in the group “observed for this
outcome” for which extra studies were identified that
did not report the outcome of interest. We judged four
of these to be potentially biased because the extra stud-
ies did not report the full results and were sponsored by
the company manufacturing the drug favoured by the
bias. We judged the other four comparisons as no bias
detected: the unavailable results were unlikely to be
missing due to non-significant p-values or the directions
of the results and unlikely to affect the overall results.
For example, selective outcome reporting bias was sus-
pected for an additional study of fluoxetine versus par-
oxetine but unlikely to affect the synthesised results
given its small sample size (21 participants) relative to
the total sample size (1364 participants). We assigned all
other comparisons observed for this outcome a level of
no bias detected in this step. The within-study assess-
ment of bias was not applicable to the 82 unobserved
comparisons.
The across-study assessment of bias was carried out
for all comparisons. We considered that bias, when
suspected, would favour the newest drug, following
the novel agent bias principle. The exceptions were
comparisons where agomelatine, paroxetine, bupro-
pion, and vortioxetine were the newest drug because
the authors obtained all unpublished data from the
manufacturers. This qualitative consideration took pri-
ority over findings from contour-enhanced funnel
plots and tests for small-study effects for comparisons
with at least 10 studies. Based on the findings from
these statistical techniques, neither amitriptyline ver-
sus fluoxetine nor citalopram versus escitalopram
would be judged at suspected bias. We nevertheless
agreed our judgement from the across-study assess-
ment of bias for both comparisons as suspected bias
favouring the newest drug because the review authors
could not exclude the possibility of hidden studies
with unfavourable results towards the newer drug in
the comparison (fluoxetine and escitalopram).
Considering the previous assessments, most of the
pairwise comparisons were considered at suspected bias
favouring the newest drug. The only ones judged with no
bias detected were all comparisons involving agomelatine
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and vortioxetine, as well as other 12 comparisons involv-
ing other drugs. The judgements for all pairwise com-
parisons are reported in the last column of the Pairwise
Comparisons Table (Additional file 7).
ROB-MEN Table
Once the Pairwise Comparison Table is complete with
all judgements, we integrate them in the ROB-MEN
Table. First, the overall risk of bias judgements for com-
parisons with direct evidence are combined with the re-
sults from the contribution matrix to calculate for each
network meta-analysis estimate the contribution coming
from direct evidence at suspected bias favouring either
of the two treatments and in total. We considered an es-
timate to have substantial contribution from evidence at
suspected bias favouring one of the two treatments in
the contrast if the difference between the first and sec-
ond column (contribution from evidence at suspected
bias favouring first and favouring second treatment, re-
spectively) was at least 15 percentage points.
The bias assessment for indirect evidence is only con-
sidered for the “only indirect” estimates and is copied
from the last column of the Pairwise Comparison Table.
This potential risk for “missing studies” is particularly
important for the indirect estimates because it drives the
bias evaluation to a “high risk” level in case there is also
substantial contribution from direct evidence with sus-
pected bias in the same direction.
The last part of the risk of bias assessment for the net-
work estimate involves running a network meta-
regression model to evaluate the presence (or absence)
of small-study effects. We run the model using the
Table 5 Proposed rules for judging the overall risk of bias due to missing evidence for network meta-analysis estimates
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smallest observed variance as a covariate and assuming
unrelated coefficients. All estimates and their adjusted
counterpart were similar, and their credible intervals had
a good level of overlap, providing no evidence of small-
study effects.
Following the rules set out in Table 4, we assign the
final judgements on the overall risk of bias due to miss-
ing evidence to the estimates and report it in the last
column of the ROB-MEN Table (Additional file 8).
Overall, the risk of bias for most estimates was classified
as some concerns or low risk. In particular, none of the
comparisons involving agomelatine, paroxetine, venla-
faxine, or vortioxetine were at high risk of bias. All 153
network meta-analysis estimates with their relative ROB-
MEN levels are reported in Table 6.
Discussion
To our knowledge, ROB-MEN is the first tool for asses-
sing the risk of bias due to missing evidence in network
meta-analysis. ROB-MEN builds on an approach re-
cently proposed for pairwise meta-analysis [1, 10] and
adapts it to the network setting. Specifically, the assess-
ments for selective outcome reporting and publication
bias in pairwise comparisons are combined with (i) the
percentage contribution of direct evidence for each pair-
wise comparison to the network meta-analysis estimates,
(ii) evidence about the presence of small-study effects,
and (iii) any bias arising from unobserved comparisons.
Our examples demonstrate that the tool applies to
different network meta-analyses, including very large
and complex networks, for which assessing the risk of
bias can be lengthy and labour-intensive. We devel-
oped an R Shiny web application [24] to facilitate the
ROB-MEN use. Once the user has evaluated the risk
of bias for all pairwise comparisons and estimates, the
app produces the Pairwise Comparisons and ROB-
MEN Table. The ROB-MEN tool is also incorporated
in the reporting bias domain of the CINeMA frame-
work and software [18, 19].
ROB-MEN is not applicable in situations where an
intervention of interest is disconnected from the net-
work. It was not designed to cover comparisons involv-
ing disconnected interventions. In case of disconnected
networks, we recommend to evaluate each subnetwork
separately. Like for any other evaluation of results’ cred-
ibility in evidence synthesis, many of the judgements in
the ROB-MEN process involve subjective decisions.
Judging bias due to missing evidence is challenging, par-
ticularly for publication bias, as reviewers will often not
know about unpublished studies. However, the subjectiv-
ity of our approach, specifically in the pairwise compari-
sons step, is shared by other approaches, as described in
the Cochrane Handbook and ROB-ME tool [1, 10]. Also,
the novel quantitative methods, the contribution matrix
[23] and network meta-regression that we integrated
into the assessment rely less on the reviewer's
subjectivity.
Table 6 League table of the network estimates and corresponding risk of bias due to missing evidence for the network of 18
antidepressants
The values in the lower triangle represent the relative treatment effect (odds ratios and 95% credible intervals) of the treatment on the top (column) versus the
treatment on the row. Colours indicate the ROB-MEN levels: green = low risk; yellow: some concerns; red = high risk. Names in the upper triangle indicate the
treatment favoured by the bias in the high risk estimates (red cells). Risk of bias assessments were obtained using the Shiny app. Ago, agomelatine; Ami,
amitriptyline; Bup, bupropion; Cit, citalopram; Clo, clomipramine; Dul, duloxetine; Esc, escitalopram; Fluo, fluoxetine; Fluvo, fluvoxamine; Mil, milnacipran; Mir,
mirtazapine; Nef, nefazodone; Par, paroxetine; Reb, reboxetine; Ser, sertraline; Tra, trazodone; Ven, venlafaxine; Vor, vortioxetine
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Conclusions
We encourage the evidence-synthesis community to
conduct studies of the reliability and reproducibility of
the ROB-MEN tool. We recommend reviewers specify
the criteria used and explain the reasoning behind the
judgements to enhance transparency. We believe that
ROB-MEN will help those performing network meta-
analyses reach better-informed conclusions and enhance
the toolbox of available methods for evaluating the cred-
ibility of network meta-analysis results.
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